Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2009. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the re-investment of dividends paid on April 9, 2009.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of share purchase transactions.
Transaction details include:
- Ordinary shares purchased at a price of £10.28 per share on April 16, 2009.
- Ordinary share ADRs purchased at a price of $30.02 per ADR on April 9, 2009.
Material Changes
The filing reports an increase in share interests for specific individuals following the dividend re-investment. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the specific number of Ordinary shares and ADRs acquired by each named director or connected person listed in the filing.
- Confirm the transaction dates (April 9 and April 16, 2009) and the corresponding share prices (£10.28 and $30.02).
- Note that this filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.